School of Medicine, Department of Biochemistry, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea; Department of Biomedical Science, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea.
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02143, USA.
DNA Repair (Amst). 2018 Aug;68:34-40. doi: 10.1016/j.dnarep.2018.06.001. Epub 2018 Jun 12.
Classical non-homologous end-joining (cNHEJ) is the main pathway for the repair of DNA double strand breaks (DSBs) in mammalian cells. In the absence of c-NHEJ, an alternative end-joining (A-EJ) mechanism resolves DSBs. To date, no A-EJ specific factor has been identified. Instead, this mechanism appears to co-opt proteins involved in more than one DNA repair pathway. These include components of base-excision repair (PARP1/XRCC1/LIG3), interstrand cross-link repair (BRCA1/FANCD2), and DSB response/DNA end-resection (MRE11A/RAD50/RBBP8). To clarify the contribution of these factors to A-EJ, here we examined their expression and recruitment to DSBs in correlation with surrogates of cNHEJ (53BP1) and homologous recombination (RAD51) in cells deficient for the cNHEJ end-ligation component XRCC4. This revealed XRCC4-deficient cells exhibited marked increases in the stability of A-EJ transcripts that result in correspondingly elevated levels of associated proteins, in comparison to WT cells. RAD51 was also increased while 53BP1 was unaffected. Treatment with radiomimetic DSB-inducing drug doxorubicin did not influence these activities. However, FANCD2, BRCA1 and XRCC1 foci, prominently associated with 53BP1 foci and hence DSBs resolved by cNHEJ, were only detected in doxorubicin-treated XRCC4-deficient cells. Strikingly, treatment of XRCC4-deficient cells with the PARP-specific inhibitor Niraparib enhanced A-EJ, and substantially induced 53BP1 transcripts and the numbers of A-EJ-associated 53BP1 DNA damage foci. RAD51 was severely inhibited, and upstream cNHEJ (KU70/KU80/DNA-PKCs/ARTEMIS) transcripts were substantially induced. These latter results were recapitulated in BRCA1-deficient cells, which contrastingly did not affect 53BP1 or PARP1 status irrespective of doxorubicin or Niraparib treatment. Hence A-EJ is regulated transcriptionally, reduced by a higher turnover rate in cNHEJ-proficient cells and sustained but fine-tuned by PARP1 in XRCC4-deficient cells to promote DNA repair and survival. Upstream cNHEJ components are similarly transcriptionally down-modulated by PARP1 and BRCA1 in a manner inversely correlated with HR and mechanistically distinct from A-EJ respectively in cNHEJ-deficient and cNHEJ-proficient settings.
经典的非同源末端连接(cNHEJ)是哺乳动物细胞中修复 DNA 双链断裂(DSBs)的主要途径。在没有 c-NHEJ 的情况下,一种替代的末端连接(A-EJ)机制可以解决 DSBs。迄今为止,还没有鉴定出 A-EJ 特异性因子。相反,这种机制似乎利用了涉及多种 DNA 修复途径的蛋白质。这些包括碱基切除修复(PARP1/XRCC1/LIG3)、链间交联修复(BRCA1/FANCD2)和 DSB 反应/DNA 末端切除(MRE11A/RAD50/RBBP8)的组成部分。为了阐明这些因素对 A-EJ 的贡献,我们在这里研究了它们在 XRCC4 缺乏的细胞中与 cNHEJ(53BP1)和同源重组(RAD51)的替代物的表达和募集与 DSBs 的相关性。这表明与 WT 细胞相比,XRCC4 缺陷细胞中 A-EJ 转录物的稳定性显著增加,导致相关蛋白水平相应升高。RAD51 也增加,而 53BP1 不受影响。用放射模拟物诱导 DSB 的药物阿霉素处理并不影响这些活性。然而,FANCD2、BRCA1 和 XRCC1 焦点,与 53BP1 焦点密切相关,因此通过 cNHEJ 解决的 DSBs,仅在阿霉素处理的 XRCC4 缺陷细胞中检测到。引人注目的是,用 PARP 特异性抑制剂尼拉帕尼处理 XRCC4 缺陷细胞增强了 A-EJ,并显著诱导了 53BP1 转录物和与 A-EJ 相关的 53BP1 DNA 损伤焦点的数量。RAD51 受到严重抑制,上游 cNHEJ(KU70/KU80/DNA-PKCs/ARTEMIS)转录物被大量诱导。这些结果在 BRCA1 缺陷细胞中得到了再现,相反,无论是否用阿霉素或尼拉帕尼处理,BRCA1 缺陷细胞都不会影响 53BP1 或 PARP1 状态。因此,A-EJ 是转录调控的,在 cNHEJ 功能正常的细胞中,由于更高的周转率而减少,而在 XRCC4 缺陷细胞中则通过 PARP1 维持但精细调节,以促进 DNA 修复和存活。PARP1 和 BRCA1 以与 HR 相反的方式,以与 cNHEJ 缺陷和 cNHEJ 功能正常的情况分别相反的方式,类似地转录下调上游 cNHEJ 成分,机制上与 A-EJ 不同。